Differences in HIV clinical outcomes amongst heterosexuals in the United Kingdom by ethnicity

Rageshri Dhairyawan\textsuperscript{a}, Hajra Okhai\textsuperscript{b}, Teresa Hill\textsuperscript{b}, Caroline A. Sabin\textsuperscript{b,c}, for the UK Collaborative HIV Cohort (UK CHIC) Study

**Objective:** We investigated differences in clinical outcomes in heterosexual participants, by ethnicity in the UK Collaborative HIV Cohort Study from 2000 to 2017.

**Design:** Cohort analysis.

**Methods:** Logistic/proportional hazard regression assessed ethnic group differences in CD4\textsuperscript{+} cell count at presentation, engagement-in-care, combination antiretroviral therapy (cART) initiation, viral suppression and rebound.

**Results:** Of 12,302 participants [median age: 37 (interquartile range: 31–44) years, 52.5% women, total follow-up: 85,846 person-years], 64.4% were black African, 19.1% white, 6.3% black Caribbean, 3.6% black other, 3.3% South Asian/other Asian and 3.4% other/mixed. CD4\textsuperscript{+} cell count at presentation amongst participants from non-white groups were lower than the white group. Participants were engaged-in-care for 79.6% of follow-up time; however, black and other/mixed groups were less likely to be engaged-in-care than the white group (adjusted odds ratios vs. white: black African: 0.70 (95% confidence interval (CI) 0.63–0.79), black Caribbean: 0.74 (0.63–0.88), other/mixed: 0.78 (0.62–0.98), black other: 0.81 (0.64–1.02)). Of 8,867 who started cART, 79.1% achieved viral suppression, with no differences by ethnicity in cART initiation or viral suppression. Viral rebound (22.2%) was more common in the black other [1.95 (1.37–2.77)], black African [1.85 (1.52–2.24)], black Caribbean [1.73 (1.28–2.33)], South Asian/other Asian [1.35 (0.90–2.03)] and other/mixed [1.09 (0.69–1.71)] groups than in white participants.

**Conclusion:** Heterosexual people from black, Asian and minority ethnic (BAME) groups presented with lower CD4\textsuperscript{+} cell counts, spent less time engaged-in-care and were more likely to experience viral rebound than white people. Work to understand and address these differences is needed.

**Background**

Due to recent advances in HIV prevention, treatment and care, new HIV infections are decreasing and life expectancy has increased for people with HIV in the UK [1,2]. UNAIDS targets of 90% of people with HIV diagnosed, 90% of these on treatment and 90% of these virally suppressed [3] were exceeded in the UK at 93–
97–97 in 2018 [2], but if the goal of ending the AIDS epidemic by 2030 is to be met, all populational groups must benefit from these advances.

Black, Asian and minority ethnic (BAME) heterosexuals are disproportionately affected by HIV in the UK with 74% (of which 57% are black African) from BAME backgrounds [1]. Of MSM, 14% are from BAME backgrounds [1] and a previous analysis of the UK Collaborative HIV Cohort (UK CHIC) study found differences in HIV outcomes amongst MSM by ethnicity [4]. Whilst there was no difference in viral suppression, BAME MSM were more likely to present at lower CD4⁺ cell counts, start combined antiretroviral therapy (cART) later and be permanently lost to follow-up than white MSM. Differences in clinical outcomes by ethnicity have also been shown in the United States, where studies have found that African Americans have lower rates of viral suppression than white communities [5,6]. However, there is a paucity of data comparing HIV outcomes by ethnic group amongst heterosexual men and women in the UK.

We aim to investigate whether there are differences in HIV clinical outcomes in the care continuum by ethnic group, amongst heterosexual women and men participating in the UK CHIC study.

Methods

The UK CHIC study, collates routine data on people with HIV, aged at least 16 years, who have attended 1 of 25 HIV clinical centres in the UK at any time from 1996 onwards. The study methods are described fully elsewhere [7]. Briefly, centres collect data on demographic information, cART history, laboratory results, and AIDS diagnoses, which are submitted annually to the co-ordinating centre. Ethnicity is based on how participants self-identify when they register with their co-ordinating centre. Ethnicity is based on how participants self-identify when they register with their HIV service. The project was approved by a Multicentre Research Ethics Committee (MREC/00/7/47) and by local ethics committees.

The analyses presented here include most recently collected data (final dataset up to 31 December 2017). Individuals reporting having acquired HIV through heterosexual sex were eligible for the study if they had attended one of 25 HIV services between 2000 and 2017; participants were followed-up from their first visit until the earliest of death, permanent loss of follow-up from HIV care (defined as failure to return for a follow-up visit within 12 months) or 31 December 2017. There was no minimum follow-up requirement for this analysis. Exclusion criteria included participants who had started cART prior to UK CHIC entry, to ensure that only those starting cART prospectively after study entry were included, as well as women who had a recorded pregnancy, which would require an enhanced approach to HIV care. Participants were grouped by ethnicity (white, black Caribbean, black African, black other, South Asian/other Asian, other/mixed).

Analyses considered CD4⁺ cell count at entry to UK CHIC and four outcomes: cART initiation was defined as any regimen including at least one protease inhibitor (boosted or nonboosted), nonnucleoside reverse transcriptase inhibitor (NNRTI) or integrase strand transfer inhibitor (INSTI) with two nucleoside reverse transcriptase inhibitors (NRTI) and no restriction on the total number of drugs in the combination. For this analysis, person-follow-up was split into a series of consecutive calendar periods, each of which started on the date of a new CD4⁺ cell count, and ended at the first of cART initiation, date of the next CD4⁺ cell count measurement, or 6 months after the measurement; engagement in care (EIC) was defined using the REACH algorithm [8] in which a person’s clinical status is used to estimate the likely time to the next scheduled follow-up appointment. Follow-up was split into consecutive monthly intervals and characteristics were determined at the start of each interval – based on this information, each person-month is classified as being ‘in-care’ or ‘out-of-care’ according to whether the person had a return visit within the expected time interval; viral load suppression, defined as an initial viral load 50 copies/ml or less in the subset of participants who initiated cART; and viral load rebound, defined on the date of the first of two consecutive viral loads more than 50 copies/ml amongst participants who suppressed HIV viral load.

Univariable and multivariable regression was used to assess the association between ethnic group and each outcome after adjustment for potential confounders. These included: sex, CD4⁺ cell count, viral load, previous AIDS, calendar year, hepatitis B/C infection, additionally cART use was adjusted for when assessing EIC, viral load suppression and time to viral rebound. To assess the association between CD4⁺ cell count and ethnicity, we used a linear regression model. Treatment initiation and ethnicity was assessed using a logistic regression model. Analyses of EIC used generalized estimating equations (GEE) to model the association between ethnicity and the binary outcome of whether each month of follow-up was deemed to be in or out of care, after adjusting for time-updated covariates. For the analyses of viral suppression, individuals who initiated cART were followed from cART initiation to the earliest of the censoring date (described above) or 12-months post cART initiation, and the time to viral load suppression was compared across the ethnic groups using Cox proportional hazards regression. Among those with viral suppression, time to viral rebound was assessed from the date of viral suppression to the earliest of viral load rebound, the censoring date or the first gap in treatment lasting for more than 14 days, with comparisons between the ethnic groups undertaken using Cox proportional
hazards regression models, after adjusting for time-updated covariates.

**Results**

**Study participants**
A total of 21,688 heterosexual individuals entered the UK CHIC study between 2000 and 2017. Of these, 9386 were excluded because of insufficient follow-up (n = 94), cART initiation prior to entry to the cohort (n = 6721) or because of a recorded pregnancy (n = 2571). Therefore, 12,302 UK CHIC participants were included and are described in Table 1 [52.5% women; median age: 37 (interquartile range – IQR: 31–44); median first CD4+ cell count: 276 (IQR: 126–450) cells/µl; median first HIV viral load: 4.1 (IQR: 3.1–4.9) log10 copies/ml]. Most participants were of black African ethnicity (64.4%) followed by white (19.1%), black Caribbean (6.3%), black other (3.7%), South Asian/other Asian (3.3%) and mixed/other (3.4%). More than half of black African (57.6%), black other (51.9%) and mixed/other (52.8%) ethnic groups were women. Individuals of black African, black other and mixed/other ethnicity entered UK CHIC at a younger median age. South Asian/other Asian participants had the highest proportion of individuals entering UK CHIC with an AIDS event. This was also present in univariable logistic regression analyses, where there was a lower odds of EIC amongst the black groups compared with the white group [black Caribbean OR: 0.77 (95% CI: 0.69–0.87); black African OR: 0.87 (95% CI: 0.81–0.93); black other OR: 0.91 (95% CI: 0.78–1.05); P < 0.0001]. After adjustment, the associations with ethnicity were strengthened as shown in Fig. 1 [black Caribbean aOR: 0.74 (95% CI: 0.63–0.88); black African aOR: 0.70 (95% CI: 0.63–0.79); black other aOR: 0.81 (95% CI: 0.64–1.02); P < 0.0001] and in addition, the aOR for the mixed/other ethnic group fell below 1 [aOR: 0.78 (95% CI: 0.62–0.98)].

**CD4+ cell count at presentation**
Upon entry to UK CHIC, individuals of all BAME groups had a lower CD4+ cell count when compared with the white group (Table 2), particularly amongst the South Asian/other Asian and black African participants. This effect was also seen in univariable linear regression analyses with a reduced impact on the mean CD4+ cell count across all BAME groups: black Caribbean parameter estimate: −36.87 [95% confidence interval (95% CI): −54.45 to −16.29]; black African: −99.00 (95% CI: −110.6 to −87.32); black other: −71.02 (95% CI: −96.54 to −45.51); South Asian/other Asian: −83.27 (95% CI: −110.54 to −56.00); mixed/other: −56.20 (95% CI: −83.29 to −30.01). After adjusting for confounders, this effect was strengthened for all BAME groups with the exception of the South Asian/other Asian category, though much greater median proportion of time EIC [median: 0.90 (IQR: 0.73–0.98)] compared with those who did not [median: 0.42 (IQR: 0.73–0.98)]. On the basis of ethnicity (Table 3), those of a South Asian/other Asian origin had the highest proportion of time spent EIC (83.6%), followed by white (80.9%) and mixed/other (80.6%) groups. Individuals of black ethnicity had the lowest (black African: 79.5%; black Caribbean: 79.3%; black other: 74.8%) proportion of time EIC. This effect was also present in univariable logistic regression analyses, where there was a lower odds of EIC amongst the black groups compared with the white group [black Caribbean OR: 0.77 (95% CI: 0.69–0.87); black African OR: 0.87 (95% CI: 0.81–0.93); black other OR: 0.91 (95% CI: 0.78–1.05); P < 0.0001]. After adjustment, the associations with ethnicity were strengthened as shown in Fig. 1 [black Caribbean aOR: 0.74 (95% CI: 0.63–0.88); black African aOR: 0.70 (95% CI: 0.63–0.79); black other aOR: 0.81 (95% CI: 0.64–1.02); P < 0.0001] and in addition, the aOR for the mixed/other ethnic group fell below 1 [aOR: 0.78 (95% CI: 0.62–0.98)].

**Treatment initiation**
Over 70% of individuals entering UK CHIC initiated a cART regimen, with 52.2% initiating treatment within the first year of UK CHIC entry. Overall, 15.8% of CD4+ cell count measurements were followed by initiation of cART. By ethnicity (Table 3), this was highest amongst participants of black African (16.7%) and black other (14.6%) groups. In a univariable logistic regression analysis, participants of black African [odds ratio (OR): 1.23 (95% CI: 1.15–1.31)] and mixed/other [OR: 1.24 (95% CI: 1.07–1.44)] ethnicity were more likely to initiate cART after a CD4+ cell count measure when compared with the white group, suggesting an association between ethnicity and treatment initiation (P < 0.0001). These associations, however, were attenuated in a multivariable logistic regression model [black African adjusted OR (aOR): 0.88 (95% CI: 0.74–1.05); mixed/other aOR: 1.08 (95% CI: 0.90–1.29)] and ethnicity was no longer associated with treatment initiation (P = 0.45) (Fig. 1).

**Time to viral suppression**
Amongst those who initiated cART, 79.1% were virally suppressed within 12 months. The white group had the highest proportion of individuals becoming virally suppressed (81.8%), followed by South Asian/other Asian (80.3%), black Caribbean (79.8%), mixed/other (78.3%), black African (78.2%) and black other (77.5%) groups (Table 3). The median time to viral suppression was 4 months (IQR: 2–8 months). This was similar across all ethnic groups (log-rank test: P = 0.86). There was no association between time to viral suppression and
Table 1. Demographic and clinical characteristics at time of entry to UK Collaborative HIV Cohort of the heterosexual participants included in the study, stratified by ethnicity.

|                     | Total (n = 12,302) | White (n = 2,345) | Black Caribbean (n = 773) | Black African (n = 7,919) | Black other (n = 449) | SA/other Asian (n = 401) | Other/mixed (n = 415) |
|---------------------|---------------------|-------------------|--------------------------|---------------------------|----------------------|--------------------------|------------------------|
| Age at UK CHIC entry (median, IQR) | Years | 37 (31–44) | 39 (30–49) | 38 (30–48) | 36 (31–43) | 36 (30–43) | 38 (31–45) | 36 (29–43) |
| HIV viral load at entry (median, IQR) | Log copies/ml | 4.1 (3.1–4.9) | 4.1 (3.2–4.9) | 4.2 (3.2–4.9) | 4.2 (3.1–4.9) | 4.2 (3.1–4.9) | 4.1 (3.0–5.1) | 4.3 (3.1–4.9) |
| Sex (n, %) | Male | 3845 (47.5%) | 1439 (61.4%) | 407 (52.7%) | 3359 (42.4%) | 216 (48.1%) | 228 (56.9%) | 196 (47.2%) |
| Female | 8457 (52.5%) | 906 (38.6%) | 366 (47.3%) | 4560 (57.6%) | 233 (51.9%) | 173 (43.1%) | 219 (52.8%) |
| Year of entry into UK CHIC (n, %) | 2000–2006 | 5105 (41.5%) | 756 (32.2%) | 343 (44.4%) | 3600 (45.5%) | 135 (30.1%) | 129 (32.2%) | 142 (34.2%) |
| 2007–2011 | 4776 (38.8%) | 927 (39.5%) | 269 (34.8%) | 3037 (38.4%) | 219 (48.8%) | 163 (40.7%) | 161 (38.8%) |
| 2012–2017 | 2421 (19.7%) | 662 (28.2%) | 161 (20.8%) | 1282 (16.2%) | 95 (21.2%) | 109 (27.1%) | 112 (27.0%) |
| Hepatitis B at entry (n, %) | 72 (0.6%) | 7 (0.3%) | 3 (0.4%) | 58 (0.7%) | 3 (0.7%) | 0 (0.0%) | 1 (0.2%) |
| Hepatitis C at entry (n, %) | 29 (0.2%) | 13 (0.6%) | 1 (0.1%) | 11 (0.1%) | 0 (0.0%) | 2 (0.5%) | 2 (0.5%) |
| AIDS at entry (n, %) | 1265 (10.3%) | 224 (9.5%) | 55 (7.1%) | 833 (10.5%) | 45 (10.0%) | 65 (16.2%) | 43 (10.4%) |
| Lost to follow up (n, %) | 108 (0.9%) | 27 (1.1%) | 7 (0.9%) | 64 (0.8%) | 3 (0.7%) | 4 (1.0%) | 3 (0.7%) |
| Died (n, %) | 631 (5.1%) | 150 (6.4%) | 57 (7.4%) | 372 (4.7%) | 22 (4.9%) | 12 (3.0%) | 18 (4.3%) |
| Initiated cART (n, %) | 8867 (72.1%) | 1714 (73.1%) | 547 (70.8%) | 5666 (71.5%) | 328 (73.0%) | 295 (73.6%) | 317 (76.4%) |

cART, combination antiretroviral therapy; IQR, interquartile range; SA, South Asian.

Table 2. Demographic and clinical characteristics at treatment initiation of the heterosexual participants in the study, stratified by ethnicity.

|                     | Total (n = 8,867) | White (n = 1,714) | Black Caribbean (n = 773) | Black African (n = 5,666) | Black other (n = 328) | SA/other Asian (n = 293) | Other/mixed (n = 317) |
|---------------------|---------------------|-------------------|--------------------------|---------------------------|----------------------|--------------------------|------------------------|
| Age at cART (median, IQR) | Years | 39 (33–46) | 42 (34–51) | 41 (34–50) | 38 (33–44) | 39 (33–45) | 39 (33–47) | 39 (32–44) |
| Year cART initiated (n, %) | 2000–2006 | 2533 (28.6%) | 338 (19.7%) | 149 (27.2%) | 1837 (32.4%) | 63 (19.2%) | 79 (26.8%) | 67 (21.1%) |
| 2007–2011 | 3864 (43.6%) | 730 (42.6%) | 209 (38.2%) | 2512 (44.3%) | 164 (50.0%) | 119 (40.3%) | 130 (41.0%) |
| 2012–2017 | 2470 (27.9%) | 646 (37.7%) | 189 (34.6%) | 137 (23.2%) | 101 (30.8%) | 97 (32.9%) | 120 (37.9%) |
| CD4⁺ count at cART (median, IQR) | cells/µl | 192 (80–309) | 232 (102–349) | 211 (90–333) | 180 (79–285) | 191 (65–303) | 160 (54–294) | 226 (95–320) |
| HIV VL at cART (median, IQR) | Log copies/mL | 4.8 (4.2–5.3) | 4.8 (4.2–5.3) | 4.8 (4.2–5.3) | 4.8 (4.2–5.3) | 4.9 (4.3–5.4) | 4.9 (4.2–5.4) | 4.8 (4.3–5.3) |
| Hepatitis B at cART (n, %) | 225 (2.5%) | 16 (0.9%) | 7 (1.3%) | 184 (3.2%) | 8 (2.4%) | 3 (1.0%) | 7 (2.2%) |
| Hepatitis C at cART (n, %) | 120 (1.3%) | 66 (3.8%) | 4 (0.7%) | 38 (0.7%) | 2 (0.6%) | 4 (1.4%) | 6 (1.9%) |
| AIDS at cART (n, %) | 1657 (18.7%) | 267 (15.6%) | 87 (15.9%) | 1120 (19.8%) | 56 (17.1%) | 68 (23.0%) | 59 (18.6%) |
| Base regimen (n, %) | NNRTI | 5596 (63.1%) | 247 (19.9%) | 333 (40.9%) | 3805 (67.1%) | 189 (57.6%) | 186 (63.1%) | 175 (55.2%) |
| PI | 2130 (24.0%) | 486 (39.2%) | 132 (24.1%) | 1244 (22.0%) | 91 (27.7%) | 58 (19.7%) | 92 (29.0%) |
| INI | 561 (6.3%) | 346 (27.9%) | 48 (8.8%) | 254 (4.5%) | 26 (7.9%) | 20 (6.8%) | 29 (9.2%) |
| Other | 580 (6.5%) | 162 (13.0%) | 34 (6.2%) | 363 (6.4%) | 22 (6.7%) | 31 (10.5%) | 21 (6.6%) |

cART, combination antiretroviral therapy; INI, integrase inhibitor; IQR, interquartile range; NNRTI, nonnucleoside reverse transcriptase inhibitor; PI, protease inhibitor; SA, South Asian.
ethnicity in either univariable or multivariable Cox regression models (Fig. 1).

**Time to viral rebound**

A total of 1489 heterosexual individuals experienced viral rebound after viral suppression. By the end of the second year of follow-up, as shown in Table 3, 16.3% of white individuals had experienced viral rebound compared with 21.6% of black Caribbean, 24.4% of black African, 22.9% of black other, 19.7% of South Asian/other Asian and 19.6% of mixed/other participants (log rank test: \( P < 0.0001 \)). In univariable Cox regression models, individuals from a BAME group were more likely to experience viral rebound, in particular those from a black group [black Caribbean hazard ratio: 1.41 (95% CI: 1.10–1.81); black African hazard ratio: 1.56 (95% CI: 1.35–1.81); black other hazard ratio: 1.63 (95% CI: 1.22–2.19)] compared with the white group. As shown in Fig. 1, these associations were strengthened in the adjusted analyses for black Caribbean [adjusted HR (aHR): 1.73 (95% CI: 1.28–2.33)], black African [aHR: 1.85 (95% CI: 1.52–2.24)], black other [aHR: 1.95 (95% CI: 1.37–2.77)] and South Asian/other Asian [aHR: 1.35 (95% CI: 0.90–2.03)] groups. In contrast there was an attenuation of this effect for the mixed/other group [aHR: 1.09 (95% CI: 0.68–1.71)].

### Table 3. Median and interquartile range or crude number and percentage of HIV outcomes among heterosexual individuals in UK Collaborative HIV Cohort, stratified by ethnic group.

| Ethnicity           | CD4⁺ cell \((n = 12302)\) | cART initiation \((n = 43336)\) | Time in-care \((n = 966658)\) | Viral suppression \((n = 8472)\) | Viral rebound \((n = 6698)\) |
|---------------------|-----------------------------|---------------------------------|-------------------------------|-------------------------------|-------------------------------|
| All                 | 276 (126–450)               | 6851 (15.8)                     | 769523 (79.6)                 | 6698 (79.1)                   | 1489 (22.2)                   |
| White               | 363 (180–547)               | 1349 (14)                       | 146701 (80.9)                 | 1324 (81.8)                   | 216 (16.3)                    |
| Black Caribbean     | 315 (160–510)               | 427 (14.4)                      | 47697 (74.8)                  | 403 (79.8)                    | 87 (21.6)                     |
| Black African       | 250 (118–410)               | 4346 (16.7)                     | 497126 (79.5)                 | 4263 (78.2)                   | 1039 (24.4)                   |
| Black other         | 288 (117–410)               | 269 (14.6)                      | 27085 (79.3)                  | 245 (77.5)                    | 56 (22.9)                     |
| South Asian/other Asian | 240 (98–430)                | 213 (15.1)                      | 26089 (83.6)                  | 228 (80.3)                    | 45 (19.7)                     |
| Mixed/other         | 311 (155–483)               | 247 (16.8)                      | 24825 (80.6)                  | 235 (78.3)                    | 46 (19.6)                     |

\( ^a \)cART initiation recorded based on treatment start after a CD4⁺ cell count measurement.

\( ^b \)Time in care percentages recorded as percentage of person-months based on EIC from the REACH algorithm. cART, combination antiretroviral therapy.

---

**Fig. 1. Adjusted ratios for HIV outcomes amongst heterosexual individuals in UK Collaborative HIV Cohort by ethnic group.**

\( ^1 \)Adjusted odds ratio; \( ^2 \)adjusted hazard ratio; \( ^3 \)time-updated co-variates. Adjusted for sex, prior history of AIDS, hepatitis B, hepatitis C, age, CD4⁺ cell count and HIV viral load. Models for EIC, viral suppression and viral rebound were additionally adjusted for combination antiretroviral therapy (cART) use.
**Discussion**

Using data from heterosexual men and women participating in the largest cohort study of people with HIV in the UK, we examined differences by ethnicity of HIV outcomes in the care continuum finding disparities in CD4+ cell count at presentation, viral rebound and engagement in care, but not cART initiation or viral suppression.

Individuals from all black, Asian and minority ethnic (BAME) groups had lower CD4+ cell counts at presentation than the white group, similar to the UK CHIC analysis of HIV outcomes in MSM by ethnicity [4] and global studies looking at late diagnosis [9–14]. Like previous London studies [15,16], there were no significant associations between ethnic group, cART initiation and time to viral suppression, suggesting that reassuringly, once linked into care there are no disparities in starting cART and becoming virally suppressed. However, all black and Asian ethnic groups were more likely to experience viral rebound than the white and mixed/other ethnic groups consistent with previous analyses of UK CHIC investigating the durability of viral suppression with first-line antiretroviral therapy [17,18]. Internationally, US studies have found that black ethnicity is associated with higher odds of having a detectable viral load [5,6] and suboptimal adherence [19]. Whilst the absolute differences in viral rebound rates between those in BAME and white groups were relatively small in our study (5–6%), these differences are clinically relevant in the context of optimal viral suppression. Black and mixed/other groups were less likely to be engaged in care than white and Asian/other Asian groups, similar to several UK studies, which showed higher rates of disengagement from care and more irregular clinic attendance for people from BAME groups and those born outside of the UK [20–23]. There are likely to be several reasons for our findings.

Firstly, social and economic disadvantage disproportionately affects black and other racially minoritized groups in the UK [24] because of structural racism and is related to poor health outcomes and reduced life expectancy [25]. People with HIV from racially minoritized backgrounds are more likely to experience social and economic hardship than people from white backgrounds [26–29] and this can impact on physical and mental health, viral rebound, access to care and quality of life [25,26,28–31].

Mental health and HIV-related stigma should also be considered. HIV-related stigma is associated with poor adherence [32] and may lead to avoidance of healthcare services [27]. A UK survey exploring HIV-related stigma found that people from BAME groups were half as likely to have discussed their diagnosis with anyone compared with white people [33] suggesting they may be more affected by HIV stigma. Mental health problems are common amongst people with HIV [34] and can impact on clinical HIV outcomes [23]. Ethnic disparities in accessing mental healthcare in the UK are well documented in the general population [35] and have been found amongst older women living with HIV [29].

Migration status may also impact on access to HIV testing, treatment and care because of recent changes in charging and data sharing between NHS Digital and the Home Office [36]. Although UK CHIC does not collect data on country of birth, national HIV surveillance data shows that 69% of people who acquired HIV through heterosexual contact were born outside of the UK [1], so it is likely many of the UK CHIC cohort were too. Studies looking at black African migrants in the UK and Europe have found that barriers to testing, treatment and care included restrictive immigration policies, lack of political will and the absence of black African representation in decision-making processes, HIV-related stigma and discrimination, competing priorities, the perception that accessing healthcare was not necessary if feeling well, and fear of involuntary disclosure [37,38].

Adherence and engagement in care may be affected by the relationship between the healthcare provider and service-user. Studies of black Africans in the UK found a lack of confidence in cART, concerns about short-term and long-term side-effects and worries that they were not being taken seriously by their healthcare provider to be important factors determining treatment adherence [39–42]. Medical mistrust should also be considered [19,39] as this has been associated with poor adherence [43]. A United States study also found that barriers to engagement in care for African American and Hispanic people also included the perception that patients were excluded from the health decision-making process, an over-emphasis on cART compared with other non-HIV-related priorities and the over institutionalization of healthcare settings, which made them feel dehumanized [44].

There are several limitations to our study. As UK CHIC collects data from NHS HIV service providers, data is from people who attend these services, not those disengaged from care. Ethnic group categories are broad, so heterogeneity within groups is missed and as ethnicity is self-identified, there may be a lack of consistency in how individuals choose their ethnic identity. In addition, we excluded women with a recorded pregnancy from the analyses. Although a higher proportion of these women were black African, than those included (77.6% vs. 64.4%), sensitivity analyses suggested that the exclusion of this group did not modify our findings greatly. Data are collected on CD4+ cell count at presentation to the HIV service, and may not necessarily reflect CD4+ cell count at diagnosis. Therefore, those who test outside of the UK may have a delay before registering with an HIV service in the UK, so their CD4+ cell count at presentation may be lower than at diagnosis.
Our study also had considerable strengths. UK CHIC is the largest HIV cohort in the UK and the contributing HIV clinics are diverse in size and location making the cohort representative of the population of people with HIV in the UK.

Our findings reinforce national recommendations to reduce late diagnosis by commissioning a range of approaches to promote and offer HIV testing [45] to ensure all population groups are targeted. Healthcare professionals working with people with HIV from BAME communities should be aware that they may need additional support to stay engaged in care and on treatment, and their needs should be assessed and managed in a proactive and holistic way. We recommend adherence support from a specialist pharmacist, access to mental health services, peer support and referral pathways to organisations that can provide advice on benefits, employment, immigration and housing. Interpreters should be made available when required.

The meaningful involvement of people with HIV is encouraged in at all stages of research, policy, service design and evaluation, and we recommend that this includes people from BAME backgrounds, so a diversity of views are represented. Further research to investigate and address the disparities we have found should take a community participatory approach.

In conclusion, using data from one of the largest and most representative cohorts of people with HIV in the UK, our results suggest that heterosexual people with HIV from BAME groups in the UK face significant barriers to testing, maintaining viral suppression and remaining engaged in HIV care. As late diagnosis, suboptimal adherence to treatment and disengagement from care are associated with HIV-related morbidity and mortality and onwards transmission, this is of significant concern. Whilst excellent progress has been made in the UK towards reaching the UNAIDS targets of ending the AIDS epidemic by 2030 and preventing new transmissions, not all groups are benefitting equally. It is, therefore, vital that these barriers are understood and addressed, so that people from black, Asian and minority ethnic groups are not left behind.

Acknowledgements

Funding: The UK CHIC Study is funded by the Medical Research Council, UK (grant numbers G0000199, G0600337, G0900274 and M004236). The study is also supported by an NIHR Senior Investigator Award to C.A.S. and through the National Institute for Health Research Health Protection Research Unit (NIHR HPRU) in Blood Borne and Sexually Transmitted Infections at University College London in partnership with Public Health England (PHE), in collaboration with London School of Hygiene & Tropical Medicine (LSHTM). The views expressed are those of the authors and not necessarily those of the NIHR, the Department of Health and Social Care or Public Health England.

Author contribution: R.D. and C.A.S. conceived of and designed the analysis, H.O. and C.A.S. carried out the statistical analysis, R.D., H.O. and C.A.S. interpreted the results and wrote the manuscript. The UK CHIC steering group critically reviewed the results and the manuscript. T.H. carried out data collection and cleaning and revision of the manuscript.

We acknowledge members of the National Institute for Health Research Health Protection Research Unit (NIHR HPRU) in Blood Borne and Sexually Transmitted Infections (BBSTI) at UCL Steering Committee: Professor Caroline Sabin (HPRU Director), Dr John Saunders (PHE Lead), Professor Catherine Mercer, Professor Gwenda Hughes, Professor Greta Rait, Dr Ruth Simmons, Professor William Rosenberg, Dr Tanyo Mbisa, Professor Rosalind Raine, Dr Sema Mandal, Dr Rosamund Yu, Dr Samreen Ijaz, Dr Fabiana Lorencatto, Dr Rachel Hunter, Dr Kirsty Foster and Dr Mamoon Tahir.

Steering Committee: Jonathan Ainsworth, Sris Allan, Jane Anderson, Ade Apoola, David Chadwick, Duncan Churchill, Valerie Delpech, David Dunn, Ian Fairley, Ashini Fox, Richard Gilson, Mark Gompels, Phillip Hay, Rajesh Hembrom, Teresa Hill, Margaret Johnson, Sophie Jose, Stephen Kegg, Clifford Leen, Dushyant Mital, Mark Nelson, Hjara Okhai, Chloe Orkin, Adrian Palfreeman, Andrew Phillips, Deenan Pillay, Ashley Price, Frank Post, Jillian Pritchard, Caroline Sabin, Achim Schwenk, Anjum Tariq, Roy Trevelion, Andy Ustianowski, John Walsh.

Central Co-ordination: University College London (David Dunn, Teresa Hill, Hjara Okhai, Andrew Phillips, Caroline Sabin); Medical Research Council Clinical Trials Unit at UCL (MRC CTU at UCL), London (Nadine van Looy, Keith Fairbrother).

Participating Centres: Barts Health NHS Trust, London (Chloe Orkin, Janet Lynch, James Hand); Brighton and Sussex University Hospitals NHS Trust (Duncan Churchill, Stuart Tilbury); Chelsea and Westminster Hospital NHS Foundation Trust, London (Mark Nelson, Richard Daly, David Asboe, Sundhiya Mandalia); Homerton University Hospital NHS Trust, London (Jane Anderson, Sajid Munshi); King’s College Hospital NHS Foundation Trust, London (Frank Post, Ade Adefisan, Chris Taylor, Zachary Glesner, Fowzia Ibrahim, Lucy Campbell); Middlesbrough, South Tees Hospitals NHS Foundation Trust, (David Chadwick, Kirsty Baillie); Mortimer Market Centre,
University College London (Richard Gilson, Ian Williams); North Middlesex University Hospital NHS Trust, London (Jonathan Ainsworth, Achim Schwenk, Sheila Miller, Chris Wood); Royal Free NHS Foundation Trust/University College London (Margaret Johnson, Mike Youle, Fiona Lampe, Colette Smith, Rob Tsintas, Clinton Chaloner, Caroline Sabin, Andrew Phillips, Teresa Hill, Hajra Okhai); Imperial College Healthcare NHS Trust, London (John Walsh, Nicky Mackie, Alan Winston, Jonathan Weber, Farhan Ramzan, Sheila Morris); North Bristol NHS Trust (Mark Gompels, Sue Allan); Leicester University Hospitals NHS Trust (Adrian Palfreeman, Adam Lewszuk); Woolwich, Lewisham and Greenwich NHS Trust (Stephen Kegg, Victoria Ogubiyi, Sue Mitchell), St. George’s Healthcare NHS Trust (Phillip Hay, Christopher Hunt, Olanike Okolo, Benjamin Wats); York Teaching Hospital NHS Foundation Trust (Ian Fairley, Sarah Russell-Sharpe, Olatunde Fagbayimu); Coventry, University Hospitals Coventry and Warwickshire NHS Trust (Sris Allan, Debra Brain); Wolverhampton, The Royal Wolverhampton Hospitals NHS Trust (Anjum Tariq, Liz Radford, Sarah Milgate); Chertsey, Ashford and St. Peter’s Hospitals NHS Foundation Trust (Jillian Pritchard, Shirley Cumming, Claire Atkinson); Milton Keynes Hospital NHS Foundation Trust (Dushyant Mital, Annie Rose, Jeanette Smith); The Pennine Acute Hospitals NHS Trust (Andy Ustianowski, Cynthia Murphy, Ilse Gunders); Nottingham University Hospitals NHS Trust (Ashini Fox, Howard Gees, Gemma Squires, Laura Anderson), Kent Community Health NHS Foundation Trust (Rajesh Hembron, Serena Mansfield, Lee Tomlinson, Christine LeHegerat, Roberta Box, Tom Hatton, Doreen Herbert), The Newcastle upon Tyne Hospitals NHS Foundation Trust (Ashley Price, Ian McVittie, Victoria Murtha, Laura Shewan); Derby Teaching Hospitals NHS Foundation Trust (Ade Apoola, Zak Connnan, Luke Gregory, Kathleen Holding, Victoria Chester, Trusha Mistry, Catherine Gatford); Public Health England, London (Valerie Delpech); i-Base (Roy Trevelion).

Conflicts of interest
R.D. has received financial support for membership of Advisory Boards, conference attendance, speaker fees and educational grants from ViVi healthcare, MSD Ltd, and Gilead Sciences. C.A.S. has received financial support for the membership of Data Safety and Monitoring Boards, Advisory Boards and for preparation of educational materials from Gilead Sciences and ViVi Healthcare.

References
1. O’Halloran C, Sun S, Nash S, Brown A, Croxford S, Connor N, et al. HIV in the United Kingdom: Towards Zero 2030. 2019 report. London: Public Health England; 2019.
2. May MT, Gompels M, Delpech V, Porter K, Orkin C, Kegg S, et al., UK Collaborative HIV Cohort (UK CHIC) Study. Impact on life expectancy of HIV-1 positive individuals of CD4+ cell count and viral load response to antiretroviral therapy. AIDS 2014; 28:1193–1202.
3. The Joint United Nations Programme on HIV/AIDS, 90-90-90. An ambitious treatment target to help end the AIDS epidemic. 2014. [C2684. Available at: http://www.unaids.org/sites/default/files/media_asset/90-90-90_en_0.pdf. [Accessed 17 November 2020].
4. United Kingdom Collaborative HIV Cohort Study Group. Uptake and outcome of combination antiretroviral therapy in men who have sex with men according to ethnic group: the UK CHIC Study. J Acquir Immune Defic Syndr 2012; 59:523–529.
5. Nance RM, Delaney JAC, Simoni JM, Wilson IB, Mayer KH, Whitney BM, et al. HIV viral suppression trends over time among HIV-infected patients receiving care in the United States, 1997 to 2015: a cohort study. Ann Intern Med 2018; 169:376–384.
6. Beer L, Bradley H, Mattson CL, Johnson CH, Hoots B, Shoupe RL. Trends in racial and ethnic disparities in antiretroviral therapy prescription and viral suppression in the United States, 2009-2013. J Acquir Immune Defic Syndr 2016; 2014:446–453.
7. UK Collaborative HIV Cohort Steering Committee. The creation of a large UK-based multicentre cohort of HIV-infected individuals: the UK Collaborative HIV Cohort (UK CHIC) Study. HIV Med 2004; 5:115–124.
8. Howarth AR, Burn KJ, Apea V, Jose S, Hill T, Delpech V, et al., UK Collaborative HIV Cohort (UK CHIC) study. Development and application of a new measure of engagement in out-patient HIV care. HIV Med 2017; 18:267–274.
9. HIV infection with late diagnosis. Public Health England. Published: 8 October 2018. Available at: https://www.ethnicity-facts-figures.service.gov.uk/health/patient-outcomes/hiv-infection-with-late-diagnosis/latest. [Accessed 17 November 2020].
10. Rice B, Elford J, Yin Z, Croxford S, Brown A, Delpech V. Trends in HIV diagnosis, HIV care, and uptake of antiretroviral therapy among heterosexual adults in England, Wales, and Northern Ireland. Sex Transm Dis 2014; 41:257–265.
11. Fakoya I, Alvarez-Del Arco D, Monge S, Copas AJ, Gennette AF, Volny-Anne A, et al., AMASE Study Team. HIV testing history and access to treatment among migrants living with HIV in Europe. J Int AIDS Soc 2018; 21 Suppl 4:e25312.
12. Wilton J, Light L, Gardner S, Rachlis B, Conway T, Cooper C, et al., Ontario HIV Treatment Network (OHTN) Cohort Study Team. Late diagnosis, delayed presentation and late presentation among persons enrolled in a clinical HIV cohort in Ontario, Canada (1999-2013). HIV Med 2019; 20:110–120.
13. Dennis AM, Naaprunik S, Seha AC, Eron JJ. Late entry to HIV care among Latinos compared with non-Latinos in a southeastern US cohort. Clin Infect Dis 2011; 53:480–487.
14. Dufus WA, Davis HT, Byrd MD, Heidari K, Stephens TG, Gibson JJ. HIV testing in women: missed opportunities. J Womens Health (Larchmont) 2012; 21:170–178.
15. Ibrahim F, Bukuti C, Anderson J. Uptake of antiretroviral treatment among people living with HIV in London: ethnicity, gender and sexual orientation. Sex Transm Infect 2008; 84:176–178.
16. Saunders P, Goodman AL, Smith CJ, Marshall N, O’Connor JJ, Lampe FC, Johnson MA. Does gender or mode of HIV acquisition affect virological response to modern antiretroviral therapy (ART)? HIV Med 2016; 17:11–19.
17. O’Connor J, Smith C, Lampe FC, Johnston MA, Chadwick DR, Nelson M, et al., UK Collaborative HIV Cohort (CHIC) Study. Durability of viral suppression with first-line antiretroviral therapy in patients with HIV in the UK: an observational cohort study. Lancet HIV 2017; 4:e295–e302.
18. Barber TJ, Geretti AM, Anderson J, Schwenk A, Phillips AN, Ranssi L, et al., UK CHIC Study Steering Committee. Outcomes in the first year after initiation of first-line HAART among heterosexual men and women in the UK CHIC Study. Antiviral Therapy 2011; 16:805–814.
19. Simoni JM, Huh D, Wilson IB, Shen J, Googin K, Reynolds NR, et al. Racial/ethnic disparities in ART adherence in the United States: findings from the MACH14 study. J Acquir Immune Defic Syndr 2012; 60:466–472.
20. Gerver SM, Chadborn TR, Ibrahim F, Vatsa B, Delpech VC, Easterbrook PJ. High rate of loss to clinical follow up among African HIV-infected patients attending a London clinic: a retrospective analysis of a clinical cohort. J Int AIDS Soc 2010; 13:29.

21. Curtis H, Yin Z, Clay K, Brown AE, Delpech VC, Ong E. BHIVA Audit and Standards Sub-Committee. People with diagnosed HIV infection not attending for specialist clinical care: UK national review. BMC Infect Dis 2015; 15:315.

22. Rice RD, Delpech VC, Chadborn TR, Elford J. Loss to follow-up among adults attending human immunodeficiency virus services in England, Wales, and Northern Ireland. Sex Trans Dis 2011; 38:685–690.

23. Howarth A, Apea V, Michie S, Morris S, Sachikonye M, Mercer C, et al. REACH: a mixed-methods study to investigate the measurement, prediction and improvement of retention and engagement in outpatient HIV care. Southampton, UK: NIHR Journals Library; 2017. Available at: https://www.journalslibrary.nihr.ac.uk/hsdr/hsdr05130/#/Abstract. [Accessed 17 November 2020].

24. Race Disparity Audit - GOV.UK. Available at: https://www.gov.uk/government/publications/race-disparity-audit. [Accessed 17 November 2020]

25. Marmot M, Allen J, Boyce T, Goldblatt P, Morrison J. Health equity in England: the Marmot Review 10 years on. London: Institute of Health Equity; 2020. Available at: https://www.health.org.uk/publications/reports/the-marmot-review-10-years-on. [Accessed 7 April 2021].

26. Ibrahim F, Anderson J, Biakatu C, Elford J. Social and economic hardship among people living with HIV in London. J Med 2008; 9:616–624.

27. Burch LS, Smith CJ, Anderson J, Sherr L, Rodger AJ, O’Connell R, et al. Socioeconomic status and treatment outcomes for individuals with HIV on antiretroviral treatment in the UK: cross-sectional and longitudinal analyses. Lancet Public Health 2016; 1:e26–e36.

28. Kall M, Kelly C, Azenbergs M, Delpech V. Positive voices: the national people living with HIV - findings from the 2017 survey. London: Public Health England; 2020.

29. Solomon D, Taru S, Allids J, Burns F, Gilson R, Sabin C, et al. Ethnic inequalities in mental health and socioeconomic status among older women living with HIV: results from the PRIME Study. Sex Transm Infect 2021. doi: 10.1136/sextrans-2020-054786. [Epub ahead of print].

30. Whiteside YO, Cohen SM, Bradley H, Skarbinski J, Hall HI, Lanksy A. Centers for Disease Control and Prevention (CDC). Progress along the continuum of HIV care among blacks with diagnosed HIV. United States, 2010. MMWR Morb Mortal Wkly Rep 2014; 63:85–89.

31. Pellowski JA, Kalichman SC, Matthews KA, Adler N. A pandemic of the poor: social disadvantage and the U.S. HIV epidemic. Am Psychol 2013; 68:197–209.

32. Katz IT, Ryu AE, Onuegbu AG, Psaros C, Weiser SD, Bangsberg DR, Tsai AC. Impact of HIV-related stigma on treatment adherence: systematic review and meta-synthesis. J Int AIDS Soc 2013; 16 (3 Suppl 2):18640.

33. The People Living with HIV Stigma Survey UK. Experiences of HIV disclosure and discrimination among Black, Asian and other Minority Ethnic groups in the United Kingdom. London, 2015. Available at: http://www.stигmaindexuk.org/posters/2016/bame-poster.pdf. [Accessed 17 November 2020].

34. Chaponda M, Aldhouse N, Kroes M, Wild J, Roderick C, Smith A. Systematic review of the prevalence of psychiatric illness and sleep disturbance as co-morbidities of HIV infection in the UK. Int J STD AIDS 2018; 29:704–713.

35. Memon A, Taylor K, Moshiala LM, Living J, Cooper M, et al. Perceived barriers to accessing mental health services among black and minority ethnic (BME) communities: a qualitative study in Southeast England. BMJ Open 2016; 6:e012337.

36. British Association for Sexual Health and HIV. HIV and British HIV Association response to Formal Review of ‘The National Health Service (Charges to Overseas Visitors) (Amendment) Regulations 2017’. Available at: https://www.bashh.org/news/news/bashh-bhiva-response-to-formal-review-of-the-national-health-service-charges-to-overseas-visitors-amendment-regulations-2017/. [Accessed 17 November 2020].

37. Burns FM, Ironie JY, Nazroo J, Johnson AM, Fenton KA. Why the(y) wait? Key informant understandings of factors contributing to late presentation and poor utilization of HIV health and social care services by African migrants in Britain. AIDS Care 2007; 19:102–108.

38. Fakoya I, Reynolds R, Caswell G, Shiripinda I. Barriers to HIV testing for migrant black Africans in Western Europe. HIV Med 2008; 9 Suppl 2:23–25.

39. Erwin J, Peters B. Treatment issues for HIV + Africans in London. Soc Sci Med 1999; 49:1519–1528.

40. Thomas F, Aggleton P, Anderson J. ‘Experts’, ‘partners’ and ‘fools’: exploring agency in HIV treatment seeking among African migrants in London. Soc Sci Med 2010; 70:736–743.

41. Spiers J, Smith JA, Poliquin E, Anderson J, Horne R. The experience of antiretroviral treatment for black West African women who are HIV positive and living in London: an interpretative phenomenological analysis. AIDS Behav 2016; 20:2151–2163.

42. Glendinning E, Spiers J, Smith JA, Anderson J, Campbell L, Cooper V, Horne R, SUPA Group. A qualitative study to identify perceptual barriers to antiretroviral therapy (ART) uptake and adherence in people living with HIV in the United States: a qualitative exploration. J Int AIDS Soc 2016; 19:1311–1321.

43. Dale SK, Bogart LM, Wagner CJ, Galvan FH, Klein DJ. Medical mistrust is related to lower longitudinal medication adherence among African-American males with HIV. J Health Psychol 2016; 21:1311–1321.

44. Freeman R, Gwadz MV, Silverman E, Kutnick A, Leonard NR, Ritchie AS, et al. Critical race theory as a tool for understanding poor engagement along the HIV care continuum among African-American/Black and Hispanic persons living with HIV in the United States: a qualitative exploration. Int J Equity Health 2017; 16:54.

45. HIV Testing: increasing uptake among people who may have undiagnosed HIV. NICE Guideline [NG60]. Published date: 01 December 2016. Date accessed: November 17, 2020.